<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5D55E165-233B-426B-B629-5FFC887C1004"><gtr:id>5D55E165-233B-426B-B629-5FFC887C1004</gtr:id><gtr:name>MRC Technology (MRCT)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8D55713A-87FD-4232-B50F-49BB01546C91"><gtr:id>8D55713A-87FD-4232-B50F-49BB01546C91</gtr:id><gtr:name>GE (General Electric Company)</gtr:name><gtr:address><gtr:line1>General Electric Company</gtr:line1><gtr:line2>3135 Easton Turnpike</gtr:line2><gtr:postCode>06828</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5D55E165-233B-426B-B629-5FFC887C1004"><gtr:id>5D55E165-233B-426B-B629-5FFC887C1004</gtr:id><gtr:name>MRC Technology (MRCT)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8D55713A-87FD-4232-B50F-49BB01546C91"><gtr:id>8D55713A-87FD-4232-B50F-49BB01546C91</gtr:id><gtr:name>GE (General Electric Company)</gtr:name><gtr:address><gtr:line1>General Electric Company</gtr:line1><gtr:line2>3135 Easton Turnpike</gtr:line2><gtr:postCode>06828</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FC381D2E-B59F-4997-BF2B-D435B2966717"><gtr:id>FC381D2E-B59F-4997-BF2B-D435B2966717</gtr:id><gtr:firstName>Patrick</gtr:firstName><gtr:otherNames>H</gtr:otherNames><gtr:surname>Maxwell</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_12012"><gtr:id>97E8CEC6-D738-4A91-9118-61BC8FB91B4A</gtr:id><gtr:title>Confidence in Concept 2012 - Cambridge</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_12012</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The Confidence in Concept scheme is a key part of MRC?s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach ?? before seeking more substantive funding.&amp;nbsp; It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.</gtr:technicalSummary><gtr:fund><gtr:end>2014-03-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-09-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>600000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>MTA - Rubinzstein</gtr:description><gtr:id>FB818FFF-3F10-4A91-A057-C57415B854E4</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>54624998980b62.85066231-1</gtr:outcomeId><gtr:partnerContribution>Confidential</gtr:partnerContribution><gtr:piContribution>Confidential</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC Technology (MRCT)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRCT- McNaughton</gtr:description><gtr:id>6FD22F87-7BC8-4021-8C50-61CCE6EA8857</gtr:id><gtr:impact>TBC</gtr:impact><gtr:outcomeId>54624ac7b1f6d9.73984007-1</gtr:outcomeId><gtr:partnerContribution>TBC</gtr:partnerContribution><gtr:piContribution>TBC</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GE Healthcare</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Franklin</gtr:description><gtr:id>286810AC-D9F2-44B6-915B-CE498B5D4C0B</gtr:id><gtr:impact>TBC</gtr:impact><gtr:outcomeId>54624b8f958988.74456593-1</gtr:outcomeId><gtr:partnerContribution>TBC</gtr:partnerContribution><gtr:piContribution>TBC</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>140000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>WT Pathfinder</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>18F87587-42CC-4591-8623-705CD0D7F733</gtr:id><gtr:outcomeId>56d577e1b2da55.52985201</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK CRT Award</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>Cancer Research Technology (CRT)</gtr:fundingOrg><gtr:id>DED97A9D-EFB9-45CC-A1EF-56287E7A4BE8</gtr:id><gtr:outcomeId>56d56941819756.16279509</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>47235</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MRC Confidence in Concept Scheme</gtr:department><gtr:description>Cox and Deegan - CiC project</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MC_PC_13059</gtr:fundingRef><gtr:id>ED02422C-C9B9-45D2-AD24-067B2AB7809A</gtr:id><gtr:outcomeId>546242cd430102.88550196</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>HEIF - Bridging</gtr:description><gtr:fundingOrg>Higher Education Innovation Funding (HEIF)</gtr:fundingOrg><gtr:id>07EBC9CE-D031-4B05-8FD0-AF83DF7F90CD</gtr:id><gtr:outcomeId>56d5740d736273.08913649</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>85500</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DFG Fellowship</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>German Research Foundation (DFG)</gtr:fundingOrg><gtr:id>0A460E8D-2FD8-468D-A86C-E920F22B3253</gtr:id><gtr:outcomeId>56d570da8b49b8.98585710</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR- EME</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>D62352E3-E6FC-4B7B-B8A6-214838FC712B</gtr:id><gtr:outcomeId>56d57cd9d7fac1.75285324</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>732800</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Super Follow on Funding</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>A212D05F-B925-48EE-BAA5-1D4E76E59B77</gtr:id><gtr:outcomeId>58c6f6516b8a51.82729619</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>GSK Biopharm Innovation Fund</gtr:description><gtr:end>2016-05-02</gtr:end><gtr:fundingOrg>GlaxoSmithKline (GSK)</gtr:fundingOrg><gtr:id>E05926B9-B346-4FF1-B348-E55E920BF195</gtr:id><gtr:outcomeId>5462461a667361.66319519</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Unknown</gtr:description><gtr:fundingOrg>Stand up to Cancer</gtr:fundingOrg><gtr:id>7770490D-6455-436D-93BC-55F390831E84</gtr:id><gtr:outcomeId>54624428180b89.97390417</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>240106</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Diabetes UK</gtr:fundingOrg><gtr:id>FA52B46F-E6EE-4DFC-9948-0CA893D8E1E4</gtr:id><gtr:outcomeId>54624597453296.76824059</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>91000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Cambridge Enterprise</gtr:department><gtr:description>Cambridge Enterprise -PoC</gtr:description><gtr:fundingOrg>University of Cambridge</gtr:fundingOrg><gtr:id>1CD9C06A-5036-4ABB-AF2A-F9BEA3115F93</gtr:id><gtr:outcomeId>56d573aeb5b6a9.15112799</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Follow on Funding</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>CE3C55B1-5617-4E37-B624-7FEC71D665FA</gtr:id><gtr:outcomeId>58c6f5ed61e616.47725332</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>SBC grant</gtr:description><gtr:fundingOrg>Higher Education Funding Council for England (HEFCE)</gtr:fundingOrg><gtr:id>8C829F69-AB7F-4880-ABDE-D9BDB4CB161D</gtr:id><gtr:outcomeId>546244a6dc8428.72852587</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Confidential</gtr:description><gtr:id>A4FBBEBB-0D09-4DF8-BF51-0A1F928701BB</gtr:id><gtr:impact>TBC</gtr:impact><gtr:outcomeId>546254ca7c6294.53724609</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Davenport et al</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Confidential</gtr:description><gtr:id>0C938312-AF2C-44DD-96F4-CCF88027CC4B</gtr:id><gtr:impact>TBC</gtr:impact><gtr:outcomeId>546253d4c93583.53467908</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Rubinzstein</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Confidential</gtr:description><gtr:id>FEF41213-A48B-4132-924C-393BDA38AE5D</gtr:id><gtr:impact>TBC</gtr:impact><gtr:outcomeId>54625505958e24.13396338</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Glen and Hiley</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Confidential</gtr:description><gtr:id>9775AF3A-82BE-4A52-A4DF-ED36D9F6E8D7</gtr:id><gtr:impact>TBC</gtr:impact><gtr:outcomeId>5462553ed58981.99179887</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Neal and Spring</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Early Clinical Evaluation - Funded by Diabetes UK

Dr Roman Hovorka will build on his successful research into an artificial pancreas for people with Type 1 diabetes to study its safety and effectiveness for the treatment of hospital inpatients with Type 2 diabetes

Research aims

Dr Roman Hovorka and his team will build on their successful studies of a prototype artificial pancreas for people with Type 1 diabetes to investigate its use for the management of Type 2 diabetes in hospital inpatients. The researchers will study the safety and effectiveness of the system in 20 inpatients with insulin-treated Type 2 diabetes over a 72-hour period. They will compare the results obtained to those achieved by 20 inpatients using conventional insulin injection therapy.
As in previous trials, the artificial pancreas system will involve using a portable computer to link a continuous glucose sensor with an insulin pump - enabling them to talk intelligently to each other. The system will continuously measure glucose levels in the body and rapidly adjust the insulin dose provided to maintain these levels within a target range.</gtr:description><gtr:id>10052C58-81E6-4347-8363-505016E909AC</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>54624ee3f1b052.32845260</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Hovorka</gtr:title><gtr:type>Therapeutic Intervention - Medical Devices</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Confidential
Under development</gtr:description><gtr:id>147E9965-E686-4BE0-A192-C721DBDA6E88</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>54625377103879.74178004</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>McNaughton &amp; Cavalla</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Detail TBC - confidentiality unclear
Stand up to cancer award obtained to fund clinical trial</gtr:description><gtr:id>86B41FEF-94F7-4126-B7C2-6143753F431B</gtr:id><gtr:impact>TBC</gtr:impact><gtr:outcomeId>546252c83b0143.31313454</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Fearon &amp; Jodrell</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>TBC</gtr:description><gtr:id>2D275688-6795-4852-9762-E7BFB39B07CF</gtr:id><gtr:impact>TBC</gtr:impact><gtr:outcomeId>5462548662bad0.50391789</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Aighbirhio</gtr:title><gtr:type>Support Tool - For Medical Intervention</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Confidential</gtr:description><gtr:id>66003DEF-EC7F-4A9B-9035-34D1AC4493C9</gtr:id><gtr:impact>TBC</gtr:impact><gtr:outcomeId>546251e71bd4c7.92726141</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Cox</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>DECA6DF4-D85D-413A-9D5E-27EC16B256D8</gtr:id><gtr:title>Coming of age: the artificial pancreas for type 1 diabetes.</gtr:title><gtr:parentPublicationTitle>Diabetologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f6477458bd5d6ee9008dfdb15621825"><gtr:id>2f6477458bd5d6ee9008dfdb15621825</gtr:id><gtr:otherNames>Thabit H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0012-186X</gtr:issn><gtr:outcomeId>5a33ec771b1f02.53643475</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB0E5FB3-5C74-41D3-87F6-F6DF0C77D6BD</gtr:id><gtr:title>Vitamin D receptor-retinoid X receptor heterodimer signaling regulates oligodendrocyte progenitor cell differentiation.</gtr:title><gtr:parentPublicationTitle>The Journal of cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a93c4c05c58736b4123f5077ef22eb14"><gtr:id>a93c4c05c58736b4123f5077ef22eb14</gtr:id><gtr:otherNames>de la Fuente AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-9525</gtr:issn><gtr:outcomeId>58b439eee13243.55234939</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E21D840-8923-4BE0-A993-799A948C2577</gtr:id><gtr:title>Retinoid X receptor activation reverses age-related deficiencies in myelin debris phagocytosis and remyelination.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a8f59949c0215e5909be69f78ef9f6d"><gtr:id>8a8f59949c0215e5909be69f78ef9f6d</gtr:id><gtr:otherNames>Natrajan MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>58b43a3fa7cc91.24975244</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D2ABDD2-1959-4270-82D2-6583725CFA0D</gtr:id><gtr:title>Mapping the binding site of TRPV1 on AKAP79: implications for inflammatory hyperalgesia.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c2e31dc94000e064483db2ff005720c"><gtr:id>1c2e31dc94000e064483db2ff005720c</gtr:id><gtr:otherNames>Btesh J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>56d5627a22b5a7.25161315</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BB07F81-5032-4AAD-90EE-C3CD74A99842</gtr:id><gtr:title>Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd46d1472086d77732425a90155ca0b4"><gtr:id>cd46d1472086d77732425a90155ca0b4</gtr:id><gtr:otherNames>Feig C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>5a33eb8ce50dc4.28090150</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD94D040-35D6-422C-8A23-44444AB961DB</gtr:id><gtr:title>Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist.</gtr:title><gtr:parentPublicationTitle>Hypertension (Dallas, Tex. : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27c0c453f7b5313da6f798f2481cd040"><gtr:id>27c0c453f7b5313da6f798f2481cd040</gtr:id><gtr:otherNames>Brame AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>56d5658f8a7042.35702417</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>898F4D34-6887-43B2-8882-69E3D0B9FDAE</gtr:id><gtr:title>Developmental Origin of Oligodendrocyte Lineage Cells Determines Response to Demyelination and Susceptibility to Age-Associated Functional Decline.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76d25ea0d9065b422553f970e220b09e"><gtr:id>76d25ea0d9065b422553f970e220b09e</gtr:id><gtr:otherNames>Crawford AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58b4331534a1c4.98863896</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C144BB2-9AFD-4051-B6A1-2B88FFDDF235</gtr:id><gtr:title>Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel-group trial</gtr:title><gtr:parentPublicationTitle>The Lancet Diabetes &amp; Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f6477458bd5d6ee9008dfdb15621825"><gtr:id>2f6477458bd5d6ee9008dfdb15621825</gtr:id><gtr:otherNames>Thabit H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a33ebe476d626.31916917</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBDDA370-8955-44B9-BF54-82F8300CB453</gtr:id><gtr:title>Glucose control in non-critically ill inpatients with diabetes: towards closed-loop.</gtr:title><gtr:parentPublicationTitle>Diabetes, obesity &amp; metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f6477458bd5d6ee9008dfdb15621825"><gtr:id>2f6477458bd5d6ee9008dfdb15621825</gtr:id><gtr:otherNames>Thabit H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1462-8902</gtr:issn><gtr:outcomeId>5a33eca99ed445.10193080</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28DB5523-CA88-4921-883A-17757EE836EC</gtr:id><gtr:title>Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system.</gtr:title><gtr:parentPublicationTitle>Trends in pharmacological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d2d5349b5b6c501408fd7ee9a8b5f226"><gtr:id>d2d5349b5b6c501408fd7ee9a8b5f226</gtr:id><gtr:otherNames>Yang P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0165-6147</gtr:issn><gtr:outcomeId>56d5658fc69570.07076876</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24F4BEEB-19D8-48C8-9A67-1CF1EAA5A11F</gtr:id><gtr:title>PI(5)P regulates autophagosome biogenesis.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebbf35f44ca269a2db6625d9a16ab871"><gtr:id>ebbf35f44ca269a2db6625d9a16ab871</gtr:id><gtr:otherNames>Vicinanza M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn><gtr:outcomeId>56d5650baa9cb0.38986207</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71CDB0A9-5A1C-4AF7-ACD3-BDE847E92807</gtr:id><gtr:title>Leucocyte subset-specific type 1 interferon signatures in SLE and other immune-mediated diseases.</gtr:title><gtr:parentPublicationTitle>RMD open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ecf0e2b46060ca9ed954b2b1dc9af38d"><gtr:id>ecf0e2b46060ca9ed954b2b1dc9af38d</gtr:id><gtr:otherNames>Flint SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2056-5933</gtr:issn><gtr:outcomeId>58b43a6ab36ab8.81977692</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_12012</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>